Cholesterol reduction and clinical benefit. Are there limits to our expectations?

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 17, Issue 12, 1997, Pages 3527-3533

  Fager, Gunnar ^a   Wiklund, Olov ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Cholesterol; Coronary heart disease; Hyperlipidemia; Hypolipidemic drugs; Prevention

Indexed keywords

CHOLESTEROL; CLOFIBRATE; COLESTYRAMINE; GEMFIBROZIL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIET; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION; TOBACCO;

EID: 0031471490     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.17.12.3527     Document Type: Article

References (30)

1. Kannel WB. Clinical misconceptions dispelled by epidemiological research. Circulation. 1995;92:3350-3360.
2. Pocock SJ, Shaper AG, Phillips AN. Concentrations of high density lipoprotein cholesterol, triglycerides, and total cholesterol in ischaemic heart disease. Br Med J. 1989;298:998-1002.
3. Pooling Project Research Group. Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events: final report of the Pooling Project. J Chron Dis. 1978;31:201-306.
4. Rosengren A, Welin L, Tsipogianni A, Wilhelmsen L. Impact of cardiovascular risk factors on coronary heart disease and mortality among middle aged diabetic men: a general population study. Br Med J. 1989;299:1127-1131.
5. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? Br Med J. 1994;308:367-372.
6. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
7. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease; the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344: 1383-1389.
8. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C-C, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
9. Holme I. An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence. Circulation. 1990;82:1916-1924.
10. Holme I. Relation of coronary heart disease incidence and total mortality to plasma cholesterol reduction in randomised trials: use of meta-analysis. Br Heart J. 1993;69:S42-S47.
11. Holme I. Cholesterol reduction and its impact on coronary artery disease and total mortality. Am J Cardiol. 1995;76:10C-17C.
12. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: a new look at old data. Circulation. 1995;91:2274-2282.
13. Committee of Principal Investigators. A cooperative trial in the prevention of ischaemic heart disease using clofibrate. Br Heart J. 1978;40:1069-1118.
14. Hjermann I, Holme I, Byre KV, Leren P. Effect of diet and smoking intervention on the incidence of coronary heart disease. Lancet. 1981;ii:1303-1310.
15. World Health Organization European Collaborative Group. Mutifactorial trial in the prevention of coronary heart disease: 3. Incidence and mortality results. Eur Heart J. 1983;4:141-147.
16. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;25:351-364.
17. Wilhelmsen L, Berglund G, Elmfeldt D, Tibblin G, Wedel H, Pennert K, Vedin A, Wilhelmsson C, Werko L. The multifactorial primary prevention trial in Göteborg, Sweden. Eur Heart J. 1986;7: 279-288.
18. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, Mäenpää H, Mälkönen M, Mänttäri M, Norola S, Pasternack A, Pikkarinen J, Romo M, Sjöblom T, Nikkilä EA. Helsinki Heart Study: primaryprevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med. 1987;317:1237-1245.
19. Research Committee to the Medical Research Council. Low fat diet in myocardial infarction: a controlled trial. Lancet. 1965;ii: 501-504.
20. Leren P. The effect of plasma cholesterol lowering diets in male survivors of myocardial infarction. Acta Med Scand. 1966; (suppl)466:1-92.
21. Research Committee to the Medical Research Council. Controlled trial of soya-bean oil in myocardial infarction. Lancet. 1968;ii: 693-700.
22. Research Committee of the Scottish Society of Physicians. Ischaemic heart disease: a secondary prevention trial using clofibrate. Br Med J. 1971;4:775-784.
23. Group of Physicians of the Newcastle upon Tyne Region. Trial of clofibrate in the treatment of ischaemic heart disease. Br Med J. 1971;4:767-775.
24. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360-381.
25. Carlsson LA, Danielsson M, Ekberg I, Klintemar B, Rosenhamer G. Reduction of myocardial infarction by the combined treatment with clofibrate and nicotinic acid. Atherosclerosis. 1977;28:81-86.
26. Dayton S, Pearce ML, Hashimoto S, Dixon WJ, Tomiyasu U. A controlled clinical trial of a diet high in unsaturated fat in preventing complications of atherosclerosis. Circulation. 1969;40:1-63.
27. Sacks FM, Wun C-C, Cole TG, et al. The influence of baseline lipid levels on reduction in coronary events by pravastatin: the Cholesterol and Recurrent Events Trial. Presented at the 69th Scientific Sessions of the American Heart Association; November 11-13, 1996, New Orleans, La.
28. Mitchel YB. The long-term tolerability profile of lovastatin and simvastatin. Atherosclerosis. 1992;97:S33-S39.
29. Illingworth DR, Tobert JA. A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin Ther. 1994;16:366-385.
30. Kjekshus J, Pedersen TR for the Scandinavian Simvastatin Survival Study Group. Reducing, the risk of coronary events: Evidence from the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol. 1995;76:64C-68C.